Limited Time Remaining to Join the Neuropsychiatric Community Online


Developing Truly Clinically Transformative Neuropsychiatric Drugs for Patients in Need

The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics.

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

  • Dive into novel therapeutic approaches for PTSD with AptinyxBionomicsTonix & MAPS 
  • Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics, NeuroRx & Intra-cellular Therapeutics
  • Explore industry approaches for innovative trial design and new methods to modelling the placebo response with NovartisOtsuka & Yale University
  • Hear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA
  • Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern

Uniting 60+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.

Attend the 2020 conference & join your online peers as we battle this unmet need.

26 World-Class Speakers Including:

Gary K. Zammit

President & CEO

Clinilabs Drug Development Corporation

Kurt Rasmussen

Director, Division of Therapeutics & Medical Consequences

The National Institute on Drug Abuse (NIDA)

Nassir Ghaemi

Translational Medicine, Neuroscience

Novartis Institutes for Biomedical Research

Phil Skolnick

Chief Scientific Officer


Seth Lederman


CEO & Chairman Tonix Pharmaceuticals

David Donabedian


Axial Biotherapeutics

Patricio O’Donnell

Executive Medical Director and Head, Neurocircuitry Biomarkers

Takeda Pharmaceuticals

Sharon Mates

Chairman, President & CEO

Intra-Cellular Therapies, Inc.

Srikanth Gottipati

Associate Director, Think Team

Otsuka Pharmaceuticals

Steve Paul

CEO and Chairman

Karuna Therapeutics, Inc

Neuropsychiatric Drug Development Summit is Proud to Partner With:

“Excellent conference with a very good and diverse set of speakers and topics”

Jim Cassella, Chief Development Officer, Concert Pharmaceuticals

t t t

“Very good conference”

Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp.

Other Events in the CNS Series: